Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a582ba661c8a7f00f3788947d6b7fbf1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_74c1bb4694ca6c9b5549cbd244ade23e |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-1806 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6907 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-336 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-336 |
filingDate |
2010-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b1263be8a3be37f640bba2de5b9ca13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4f4267461e65918d26eb36eef706c3f |
publicationDate |
2011-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2011014124-A1 |
titleOfInvention |
Targeted atherosclerosis treatment |
abstract |
This invention relates generally to methods for ameliorating at least one symptom or aspect of atherosclerosis. The methods include administration of targeted carrier compositions comprising a therapeutic agent effective in ameliorating at least one aspect of atherosclerosis coupled to a targeting ligand effective is targeting the therapeutic agent to tissue associated with atherosclerotic plaque. |
priorityDate |
2004-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |